References
- Davies D E, Chamberlin S G. Targeting the epidermal growth factor receptor for therapy of carcinomas. Biochem Pharmacol 1996; 51: 1101–10
- Newman R A, Vidal J C, Vistakis L J, Johnson J, Etcheverry M A. VRCTC-310. A novel compound of purified animal toxins separates antitumor efficacy from neurotoxicity. Inv New Drugs 1993; 11: 151–9
- Newman R A, Yu Y H, Xu F J, Thornton A, Bast R C., Jr, Von Hoff D D, et al. Cellular pharmacology and cytotoxicity of crotoxin, a phospholipase A2 toxin, against human breast, colon and ovarian cancer cell lines. Proc Annu Meet Am Assoc Cancer Res 1996; 37: A2685
- Donato N J, Martin C A, Perez M, Newman R A, Vidal J C, Etcheverry M. Regulation of epidermal growth factor receptor activity by crotoxin, a snake venom phospholipase A2 toxin. Anovel growth inhibitory mechanism. Biochem Pharmacol 1996; 51: 1535–43
- Krizaj I, Faure G, Gubensek F, Bon C. Neurotoxic phospholipases A2 ammodytoxin and crotoxin bind to distinct high-affinity protein acceptors in Torpedo marmorata electric organ. Biochemistry 1997; 36: 2779–87
- DeTolla L J, Stump K C, Russell R, Vistakis L J, Vidal J G, Newman R A, Etcheverry M A. Toxicity of the novel animal-derived anticancer agent, VRCTC-310: acute and subchronic studies in beagle dogs. Toxicology 1995; 99: 31–46
- Villarrubia V G. The biological response against cancer and infections. Biological Response Modifiers (in Spanish). PhD in Preventive Medicine. Faculty of Medicine, Universidad Complutense, MadridSpain 1992
- Costa L A, Coni-Molina C, Miles H, Diez R A, Cervellino J C. Phase I study of VRCTC, a purified snake venom fraction in patients with refractory cancer. Safety and pharmacokinetic data. Proc 33 Annu Meet Am Soc Clin Oncol. 1997; A820
- Freitas T V, Frezard F. Encapsulation of native crotoxin in liposomes: a safe approach for the production of antivenom and vaccination against Crotalus durissus terrificus venom. Toxicon 1997; 35: 91–100
- Villarrubia V G, Alvárez-Mon M, Chirigos M A, Herrerias J M. Hepatitis B virus (HBV) and the inflammatory/immune response: The natural environment of the antigen presentation and the virally-induced immunologic chaos. Rev Esp Enf Digest (Spain), Accepted for publication
- Villarrubia V G, Márquez P, Cobo J, Sada G. AM3, an oral BRM: A protective agent against iatrogenic bone marrow and liver damages in breast cancer patients under conventional adjuvant radiochemotherapy. Can J Infect Dis 1992; 3(B)138–42